ArticleIndian journal of pharmacology2026
Impact of atypical antipsychotics on cytokine profiles in schizophrenia: An 8-week longitudinal study.
Article in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia has traditionally been conceptualized through dopaminergic and glutamatergic frameworks. In recent years, attention has increasingly focused on the role of immune dysregulation in its pathophysiology, although conclusive evidence remains limited. In this context, the present study aimed to investigate alterations in cytokine profiles and their association with clinical symptomatology following treatment with atypical antipsychotics for 8 weeks. MATERIALS AND
methodsThirty patients aged 18-65 years, diagnosed with schizophrenia as per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria, were enrolled. Participants received atypical antipsychotic therapy as clinically indicated. Symptom severity was assessed using the Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms (SANS). Serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), and regulated upon activation, normal T-cell expressed and secreted (RANTES) were measured at baseline and after 8 weeks of therapy.
resultsMedian SAPS and SANS scores significantly decreased from 39 to 30.5 (P < 0.001) and from 30 to 28 (P < 0.001), respectively. Correspondingly, median serum TNF-α levels declined from 28.55 (6.51-227) to 19.98 (4.56-145) pg/mL (P = 0.033). Reductions were also observed for IL-8 (62.2-50.25 pg/mL; P = 0.171) and RANTES (520-500 pg/mL; P = 0.758).
conclusionTreatment with atypical antipsychotics significantly attenuated both positive and negative symptoms and reduced TNF-α levels in patients with schizophrenia. The concomitant decline in cytokine concentrations suggests a potential immunomodulatory effect of treatment, highlighting TNF-α, IL-8, and RANTES as possible prognostic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.